Share Issue in connection with the acquisition of Precision Micro Devices, LLC

Jyllinge, Denmark, May 31, 2010, ORIGIO a/s (OSE: ORO), a leader in Assisted Reproductive Technologies (ART), announced today that it has completed a share issue of 298,648 new shares.

The new shares will be used as an advanced payment in connection with the acquisition of Precision Micro Devices, LLC (PMD). ORIGIO announced the acquisition of PMD on May 11, 2010, and expects to close the transaction on June 1, 2010.

The share issue was based on a USD/NOK exchange rate of 6.4508 (closing rate on May 31, 2010) and at a price of NOK 10.80 per share, which is the mean average closing price on the Oslo Stock Exchange for the seven trading days prior to today.

After the completion of the share issue the total nominal value of ORIGIO a/s share capital is NOK 143,457,725 at the end of May 31, 2010, which is made up of 28,691,545 shares of a nominal value of NOK 5 each corresponding to 28,691,545 votes.

For further information, please contact:
Jesper Funding Andersen, CEO: +45 4073 0963 or E-mail: jfandersen@origio.com
Jakob Brix Christensen, Director Investor Relations: +45 2144 4811 or E-mail: jbrix@origio.com

About ORIGIO a/s
ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to medical professionals to help the #1 dream of every infertile couple come true. ORIGIO currently comprises the three product families MediCult Media, Humagen Pipets and MidAtlantic Devices, that caters for the broadest range of ART requirements. ORIGIO, which is headquartered in Jyllinge, Denmark and has companies in 9 countries, is listed on the Oslo Stock Exchange (ORO). For further  information, please visit www.origio.com.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this press release will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO’s anticipated schedule. These factors, and other factors, including, but not limited to those described in ORIGIO’s most recent annual report, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time.
ORIGIO does not assume any responsibility for updating any forward-looking statements.